ProCE Banner Activity

CME

Recent Changes to MCL Treatment Landscape

Video

On-demand webcast of expert faculty presentation on recent changes in the mantle cell lymphoma treatment landscape and case discussion on how these changes can be applied in clinical practice.

Physicians: Maximum of 1.75 AMA PRA Category 1 Credits

Released: December 14, 2023

Expiration: December 13, 2024

Share

Faculty

Ann LaCasce

Ann LaCasce, MD, MMSc

Associate Professor of Medicine
Lymphoma Program
Dana-Farber Cancer Institute
Boston, Massachusetts

John P. Leonard

John P. Leonard, MD

Senior Associate Dean for Innovation and initiatives
Chair (Interim), Weill Department of Medicine
Richard T. Silver Distinguished Professor of Hematology and Medical Oncology
Weill Cornell Medicine/NewYork-Presbyterian
New York, New York

Matthew Lunning

Matthew Lunning, DO, FACP

Associate Professor
Fred & Pamela Buffett Cancer Center
University of Nebraska Medical Center
Omaha, Nebraska

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by an educational grant from AstraZeneca.

AstraZeneca

Target Audience

This program is intended for physicians and other healthcare professionals who care for patients with mantle cell lymphoma.

Program Learning Goal

The goal of this program is to improve the knowledge and competence of learners in effort to optimize treatment for patients with mantle cell lymphoma.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Select optimal first-line treatment for patients with MCL who are not candidates for aggressive therapy

  • Develop BTKi-based therapeutic strategies for patients with newly diagnosed MCL who are eligible for ASCT

  • Plan BTKi-based therapeutic strategies for patients with R/R MCL, taking into consideration guideline recommendations, new indications, and recent practice-changing clinical trial results

  • Manage treatment-related symptoms in patients with MCL receiving BTKi-based therapy to optimize adherence and clinical outcomes

  • Identify patients with MCL who may be eligible for ongoing clinical trials evaluating currently available and emerging BTKis and BTKi-based combinations

Disclosure

Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:

Program Director

John P. Leonard, MD

Senior Associate Dean for Innovation and initiatives
Chair (Interim), Weill Department of Medicine
Richard T. Silver Distinguished Professor of Hematology and Medical Oncology
Weill Cornell Medicine/NewYork-Presbyterian
New York, New York

John P. Leonard, MD: consultant/advisor/speaker: AbbVie, Astellas, AstraZeneca, Bayer, Beigene, Bristol-Myers Squibb, Calithera, Caribou Biosciences Constellation, Eisai, Eipizyme, Genmab, Grail, Incyte, Janssen, Lilly, MEI Pharma, Merck, Mustang, Novartis, Pfizer, Roche/Genentech, Seagen, Second Genome, Sutro.

Primary Author

Ann LaCasce, MD, MMSc

Associate Professor of Medicine
Lymphoma Program
Dana-Farber Cancer Institute
Boston, Massachusetts

Ann S. LaCasce, MD, MMSc: consultant/advisor/speaker: Kite Pharma, Seagen.

Matthew Lunning, DO, FACP

Associate Professor
Fred & Pamela Buffett Cancer Center
University of Nebraska Medical Center
Omaha, Nebraska

Matthew Lunning, DO, FACP: consultant/advisor/speaker: AbbVie, Acrotech, ADC Therapeutics, Astellas, AstraZeneca, Bristol-Myers Squibb, Daiichi Sankyo, EUSA, Fate Therapeutics, Genentech, Genmab, Janssen/Pharmacyclics, Kite, Morphosys, Nurix Therapeutics, Pharmacyclics, Seattle Genetics, TG Therapeutics; research support: Bristol-Myers Squibb, Curis. 

The planners and content peer reviewers from Clinical Care Options, LLC do not have any relevant financial relationships to disclose.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 1.75 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from December 14, 2023, through December 13, 2024:

  1. Login or Sign Up for an account by clicking at the top of this page.
  2. Read the target audience, learning objectives, and faculty disclosures.
  3. View and study the content in its entirety.
  4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65 and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the confirmation page. Records of all CME/CE activities completed can be found on the "My Certificates" page. There are no costs/fees for this activity.

Format

This program has been made available online.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

CCO designates this enduring material for a maximum of 1.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.